EFPIA Newsletter 17 September 2020

COVID-19 vaccines: Why safety always comes first     Nathalie Moll for Euractiv   With the eyes of the world focused on the development of COVID-19 vaccines to address the devastating health and economic consequences of this truly global pandemic, the news that clinical trials of one of the candidate vaccines had been halted may have caused hearts to sink. In reality, it underlined the priority commitment to the safety of everyone involved in fighting the coronavirus. In short it showed that the system is working. Read more →

Our latest statements     17 September 2020 Vaccines Europe Statement on the safety of COVID-19 vaccines The health and safety of people receiving any vaccine is our first priority, and that applies equally to recipients... Read more →         17 September 2020 Joint statement of European Pharmaceutical Industry Associations on the European Parliament’s... We are committed to continuing to work with the European institutions and other stakeholders to deliver tangible progress... Read more →         16 September 2020 EFPIA Statement on the State of the Union Address The COVID-19 crisis has underlined the importance of Europe’s health research eco-system, our resilience to health threats,... Read more →

19 Conversations | The EFPIA podcast series

World Patient Safety Day

	Will COVID-19 vaccines be safe? Across the World, pharmaceutical companies and regulatory agencies are joining forces to find a safe and effective COVID-19 vaccine. We’re working round the clock to stop COVID-19 in its tracks, but speed will not overcome safety.		Can you make enough COVID-19 vaccine to supply the whole world? We’re working at an unprecedented rate, whilst ensuring we never compromise when it comes to safety.

Events     18 SEP 2020   Understand diabetes, rethink diabetes, share solutions Virtual event Are we doing the best we can for the 60 million Europeans living with diabetes? Learn more →       21 SEP 2020   Every day counts Virtual event Accelerate access. Beat cancer. Learn more →

	22 SEP 2020			Oncology Virtual Partnering Virtual event Where the best science in oncology comes to meet Learn more →

	24 SEP 2020			How can the EU establish global leadership through an ambitious trade policy? Virtual event Join us to debate on what the best way forward for EU Trade policy can be Learn more →

	28 SEP 2020			Neurological diseases: Lessons learnt from COVID and the future of neuroscience Virtual event EFNA, EFPIA and EBC are delighted to invite you to join this virtual event. Learn more →

	02 NOV 2020			Clinical Trials Europe Virtual event Secure a free pass* to Europe’s largest event dedicated to streamlining clinical trials and improving patient outcomes... Learn more →

What we are reading UK’s MHRA allows restart of Oxford/AstraZeneca Covid-19 vaccine trials 14 September 2020  (ClinicalTrials) Read more → Europe’s health after COVID-19 14 September 2020  (Euractiv) Read more → EHDEN launches its 3rd open call for data partners! 15 September 2020  (EHDEN website) Read more →

About the EFPIA newsletter The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55 Communications@efpia.eu ▶ in

EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe